Drug Discovery Opinion

The precise cause of psoriasis is not known but a number of factors, such as skin injury and infection, are thought to trigger outbreaks. T-cells become activated, leading to an acceleration of the normal replacement processes of the skin and an accumulation of skin cells as plaques on the surface of the skin. First line treatments include emollients and topical application of drugs such as vitamin D derivatives, coal tar preparations, steroids, vitamin A derivatives and dithranol. For refractory cases, retinoids or immunosuppressants may be prescribed. A recent study shows that the selective PKC inhibitor, AEB071, may become a new therapeutic option for the treatment of psoriasis. At a dose of 300 mg bid, AEB071 was well tolerated and improved the symptoms of psoriasis within a 2-week treatment period.

AEB071 is also undergoing clinical trials in kidney and liver transplant patients.

Bookmark It

Hide Sites

Related posts:

1. LRRK2 Inhibitor Protective in Parkinson’s Disease Model The main symptoms of Parkinson’s disease are tremor, rigidity and involuntary movement, caused by loss of dopaminergic neurons in the...
2. Rational Design of New Type II Kinase Inhibitor Protein kinases play important roles in regulating most cellular processes and are commonly activated in cancer cells. A number of...
3. mTORC1 and MAPK Inhibitors for Treatment of Cancer Rapamycin is a macrolide antibiotic used as an immunosuppressant to prevent organ rejection in transplant patients. Rapamycin and analogues have...
4. New Target for Malignant Melanoma Malignant melanoma is the most aggressive form of skin cancer, involving malignant transformation of melanocytes. Although it is one of...

Related posts brought to you by Yet Another Related Posts Plugin.

 Email This Post

This entry was posted on Friday, September 26th, 2008 at 8:30 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.